BR112017012042A2 - composição de conjugado anticorpo-droga e método para tratar câncer de mama - Google Patents
composição de conjugado anticorpo-droga e método para tratar câncer de mamaInfo
- Publication number
- BR112017012042A2 BR112017012042A2 BR112017012042A BR112017012042A BR112017012042A2 BR 112017012042 A2 BR112017012042 A2 BR 112017012042A2 BR 112017012042 A BR112017012042 A BR 112017012042A BR 112017012042 A BR112017012042 A BR 112017012042A BR 112017012042 A2 BR112017012042 A2 BR 112017012042A2
- Authority
- BR
- Brazil
- Prior art keywords
- antibody
- breast cancer
- treating breast
- drug conjugate
- conjugate composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
- A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
é divulgado um conjugado anticorpo-droga (adc) que tem um anticorpo igg que se liga a um alvo c-met conjugado a ambos os sítios cys na região de dobradiça de um anticorpo igg. é ainda divulgado um método para tratar um câncer de mama que compreende fornecer uma quantidade efetiva de um adc c-met.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462089203P | 2014-12-08 | 2014-12-08 | |
PCT/US2015/064571 WO2016094455A1 (en) | 2014-12-08 | 2015-12-08 | C-met antibody drug conjugate |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112017012042A2 true BR112017012042A2 (pt) | 2018-01-16 |
Family
ID=56108080
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112017012042A BR112017012042A2 (pt) | 2014-12-08 | 2015-12-08 | composição de conjugado anticorpo-droga e método para tratar câncer de mama |
Country Status (12)
Country | Link |
---|---|
US (2) | US20180280531A1 (pt) |
EP (1) | EP3229846A1 (pt) |
JP (1) | JP2018502149A (pt) |
AU (1) | AU2015360724A1 (pt) |
BR (1) | BR112017012042A2 (pt) |
CA (1) | CA2969892A1 (pt) |
EA (1) | EA201791203A1 (pt) |
IL (1) | IL252441A0 (pt) |
MA (1) | MA40725A (pt) |
PH (1) | PH12017501021A1 (pt) |
SG (1) | SG11201704458SA (pt) |
WO (1) | WO2016094455A1 (pt) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2975383C (en) * | 2015-01-28 | 2023-09-12 | Sorrento Therapeutics, Inc. | Antibody drug conjugates comprising dolastatin derivatives |
WO2016127081A1 (en) * | 2015-02-06 | 2016-08-11 | Sorrento Therapeutics, Inc. | Antibody drug conjugates |
WO2018069851A2 (en) * | 2016-10-11 | 2018-04-19 | Sorrento Therapeutics, Inc. | C-met antibody drug conjugate |
TWI782930B (zh) | 2016-11-16 | 2022-11-11 | 美商再生元醫藥公司 | 抗met抗體,結合met之雙特異性抗原結合分子及其使用方法 |
RS61967B1 (sr) * | 2016-11-23 | 2021-07-30 | Lilly Co Eli | Konjugati leka i met antitela |
SG10202109376YA (en) * | 2017-02-28 | 2021-10-28 | Immunogen Inc | Maytansinoid derivatives with self-immolative peptide linkers and conjugates thereof |
WO2019189453A1 (en) * | 2018-03-28 | 2019-10-03 | Mitsubishi Tanabe Pharma Corporation | DRUG CONJUGATES OF cMET MONOCLONAL BINDING AGENTS, AND USES THEREOF |
WO2020014306A1 (en) * | 2018-07-10 | 2020-01-16 | Immunogen, Inc. | Met antibodies and immunoconjugates and uses thereof |
CA3146933A1 (en) | 2019-09-16 | 2021-03-25 | Marcus KELLY | Radiolabeled met binding proteins for immuno-pet imaging |
US20240050583A1 (en) * | 2020-12-08 | 2024-02-15 | Harbour Biomed (Shanghai) Co., Ltd | Protein-drug conjugate and site-specific conjugating method |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009099741A1 (en) * | 2008-02-01 | 2009-08-13 | Genentech, Inc. | Nemorubicin metabolite and analog reagents, antibody-drug conjugates and methods |
CN104640572B (zh) * | 2012-05-15 | 2018-04-27 | 索伦托医疗有限公司 | 药物偶联物,偶联方法,及其用途 |
EP2861261A2 (en) * | 2012-06-19 | 2015-04-22 | Polytherics Limited | Process for preparation of antibody conjugates and antibody conjugates |
WO2013192594A2 (en) * | 2012-06-21 | 2013-12-27 | Sorrento Therapeutics Inc. | Antigen binding proteins that bind c-met |
-
2015
- 2015-12-08 US US15/533,360 patent/US20180280531A1/en not_active Abandoned
- 2015-12-08 JP JP2017549176A patent/JP2018502149A/ja active Pending
- 2015-12-08 MA MA040725A patent/MA40725A/fr unknown
- 2015-12-08 CA CA2969892A patent/CA2969892A1/en not_active Abandoned
- 2015-12-08 SG SG11201704458SA patent/SG11201704458SA/en unknown
- 2015-12-08 EA EA201791203A patent/EA201791203A1/ru unknown
- 2015-12-08 US US14/963,190 patent/US20170281796A1/en not_active Abandoned
- 2015-12-08 AU AU2015360724A patent/AU2015360724A1/en not_active Abandoned
- 2015-12-08 WO PCT/US2015/064571 patent/WO2016094455A1/en active Application Filing
- 2015-12-08 EP EP15866409.4A patent/EP3229846A1/en not_active Withdrawn
- 2015-12-08 BR BR112017012042A patent/BR112017012042A2/pt not_active IP Right Cessation
-
2017
- 2017-05-22 IL IL252441A patent/IL252441A0/en unknown
- 2017-06-01 PH PH12017501021A patent/PH12017501021A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
SG11201704458SA (en) | 2017-06-29 |
IL252441A0 (en) | 2017-08-31 |
AU2015360724A1 (en) | 2017-07-13 |
US20180280531A1 (en) | 2018-10-04 |
US20170281796A1 (en) | 2017-10-05 |
JP2018502149A (ja) | 2018-01-25 |
EP3229846A1 (en) | 2017-10-18 |
CA2969892A1 (en) | 2016-06-16 |
WO2016094455A1 (en) | 2016-06-16 |
EA201791203A1 (ru) | 2018-04-30 |
WO2016094455A8 (en) | 2016-12-01 |
MA40725A (fr) | 2017-10-18 |
PH12017501021A1 (en) | 2017-12-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112017012042A2 (pt) | composição de conjugado anticorpo-droga e método para tratar câncer de mama | |
CL2018003758A1 (es) | Conjugados anticuerpo anti-dll3-fármaco y métodos de uso. (divisional solicitud 201800458) | |
PH12020500240A1 (en) | Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies | |
BR112017004953A2 (pt) | imunoconjugado, formulação farmacêutica, método de tratamento e método de inibição da proliferação de uma célula | |
CO2017010618A2 (es) | Anticuerpos contra icos | |
BR112017023849A2 (pt) | anticorpos anti-ox40 e métodos de uso dos mesmos | |
BR112016026993A2 (pt) | combinação de um anticorpo anti-ccr4 e um agonista 4-1bb para tratar câncer | |
BR112016022910A2 (pt) | anticorpos contra her2 biespecíficos | |
BR112018068461A2 (pt) | conjugado, composição farmacêutica, métodos para preparação de um conjugado e para alívio de um sintoma de um câncer. | |
BR112017027990A2 (pt) | modulação imune e tratamento de tumores sólidos com anticorpos que se ligam especificamente ao cd38 | |
CO2017004782A2 (es) | Conjugados de anticuerpo- farmaco | |
BR112017009263A2 (pt) | anticorpo ou fragmento do mesmo que se liga a uma cd38 humana, anticorpo biespecífico, anticorpo ou fragmento do mesmo que se liga a cd38 humana e de cinomólgos, epítopo sobre a cd38 humana solúvel, composição e imunoconjugado | |
BR112018000212A2 (pt) | uso combinado de anticorpos anti pd-1 e anti m-csf no tratamento de câncer | |
CL2016002548A1 (es) | Derivados de tubulisina | |
BR112015030514A2 (pt) | Composições e métodos para conjugação de anticorpos ativáveis | |
BR112015029969A2 (pt) | tratamento de câncer usando moduladores de isoformas quinase pi3 | |
BR112016025470A2 (pt) | ?hdl terapêutico? | |
PE20160753A1 (es) | Terapia combinada con un anticuerpo anti-ang2 y un agonista de cd40 | |
BR112017006468A2 (pt) | anticorpo biespecífico, composição farmacêutica, kit, uso de uma combinação de um anticorpo biespecífico e método de tratamento de câncer | |
BR112018000650A2 (pt) | anticorpos anti-tfr e sua utilização no tratamento de trastornos proliferativos e inflamatórios | |
BR112015027309A2 (pt) | anticorpo, composição, método de tratamento e uso de um anticorpo | |
BR112017011234A2 (pt) | anticorpos contra receptor da barreira hematoencefálica e métodos de uso | |
CR20150668A (es) | Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso | |
BR112016029842A2 (pt) | conjugados de anticorpo anti-cd22-fármaco e métodos de uso dos mesmos | |
CL2016001753A1 (es) | Anticuerpo monoclonal humanizado que se une específicamente a netrina-1, composiciones farmacéuticas y usos del anticuerpo para el tratamiento del cáncer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B15K | Others concerning applications: alteration of classification |
Ipc: A61K 47/00 (2006.01) |
|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 3A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2494 DE 23-10-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |